BTIG Research cut shares of TRACON Pharmaceuticals (NASDAQ:TCON) from a buy rating to a neutral rating in a report published on Friday morning, The Fly reports.
TCON has been the topic of a number of other reports. Needham & Company LLC reaffirmed a buy rating and issued a $7.00 price target on shares of TRACON Pharmaceuticals in a research note on Friday, March 1st. Zacks Investment Research raised TRACON Pharmaceuticals from a sell rating to a hold rating in a research note on Saturday, January 5th.
Shares of TRACON Pharmaceuticals stock opened at $0.67 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.01 and a current ratio of 3.01. The company has a market capitalization of $19.80 million, a price-to-earnings ratio of -0.52 and a beta of 3.10. TRACON Pharmaceuticals has a one year low of $0.50 and a one year high of $3.20.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD.
Further Reading: Is it Safe to Invest in Commodities?
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.